A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy
- 30 October 2019
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (1), 50-52
- https://doi.org/10.1002/cpt.1661
Abstract
No abstract availableKeywords
Funding Information
- Moffitt Cancer Center (P30‐CA076292)
- National Center for Complementary and Integrative Health (R21AT009475)
- National Institutes of Health (R24GM115264, U24HG010135, R24GM61374, R24 GM123930)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54 HD090258, R01HD089928)
This publication has 7 references indexed in Scilit:
- Concentration–Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference RangesTherapeutic Drug Monitoring, 2019
- Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive DisordersFrontiers in Pharmacology, 2019
- Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 PatientsAmerican Journal of Psychiatry, 2018
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateClinical Pharmacology & Therapeutics, 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology & Therapeutics, 2015
- Emergency Department Visits by Adults for Psychiatric Medication Adverse EventsJAMA Psychiatry, 2014
- Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysisProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011